<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cáncer de la unión gastroesofágica &#8211; Grupo TTD</title>
	<atom:link href="https://grupottd.org/tag/cancer-de-la-union-gastroesofagica/feed/" rel="self" type="application/rss+xml" />
	<link>https://grupottd.org</link>
	<description>Grupo de Tratamiento de los Tumores Digestivos</description>
	<lastBuildDate>Mon, 01 Jun 2026 06:32:52 +0000</lastBuildDate>
	<language>es</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://grupottd.org/wp-content/uploads/2026/03/cropped-Logo-TTD-favicon-32x32.png</url>
	<title>Cáncer de la unión gastroesofágica &#8211; Grupo TTD</title>
	<link>https://grupottd.org</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Claudina 18.2 en adenocarcinoma gastroesofágico: prevalencia, solapamiento biomarcador e impacto clínico en cohorte europea</title>
		<link>https://grupottd.org/claudina-18-2-en-adenocarcinoma-gastroesofagico-prevalencia-solapamiento-biomarcador-e-impacto-clinico-en-cohorte-europea/</link>
					<comments>https://grupottd.org/claudina-18-2-en-adenocarcinoma-gastroesofagico-prevalencia-solapamiento-biomarcador-e-impacto-clinico-en-cohorte-europea/#respond</comments>
		
		<dc:creator><![CDATA[Susana Rodríguez]]></dc:creator>
		<pubDate>Mon, 01 Jun 2026 06:31:38 +0000</pubDate>
				<category><![CDATA[Artículos comentados]]></category>
		<category><![CDATA[Adenocarcinoma gastroesofágico]]></category>
		<category><![CDATA[Biomarcadores]]></category>
		<category><![CDATA[Cáncer de la unión gastroesofágica]]></category>
		<category><![CDATA[Cáncer gástrico]]></category>
		<category><![CDATA[Claudina 18.2]]></category>
		<category><![CDATA[CLDN18.2]]></category>
		<category><![CDATA[ESMO Open]]></category>
		<category><![CDATA[Estudio multicéntrico europeo]]></category>
		<category><![CDATA[HER2 positivo]]></category>
		<category><![CDATA[inmunoterapia]]></category>
		<category><![CDATA[PD-L1]]></category>
		<category><![CDATA[zolbetuximab]]></category>
		<guid isPermaLink="false">https://grupottd.org/?p=13154</guid>

					<description><![CDATA[El estudio de Terán et al. analiza la expresión de CLDN18.2 en 563 pacientes europeos con adenocarcinoma gastroesofágico avanzado. La expresión alta de CLDN18.2 (≥75% de células tumorales) se detectó en el 48,3% de los casos, una prevalencia superior a la de los ensayos pivotales. La expresión se asoció con histología difusa y afectación peritoneal, y se solapó con otros biomarcadores en más del 20% de los pacientes. Mientras que CLDN18.2 no modificó los resultados con quimioterapia sola, sí se asoció con mejor respuesta a la terapia anti-HER2 y con una tendencia a peores resultados con inmunoterapia.

Conclusiones:
-	La expresión alta de CLDN18.2 es más prevalente en Europa (48,3%) que en las series asiáticas y los ensayos pivotales (~24-38%).
-	Se asocia con histología difusa, células en anillo de sello y afectación peritoneal.
-	No tiene impacto en los resultados de supervivencia con quimioterapia de primera línea.
-	En los tumores HER2 positivos, aquellos con expresión alta de CLDN18.2 se asociaron con mejor mSLP con terapia anti-HER2 (17 vs 8,9 meses; P = 0,03).
-	Los pacientes con tumores expresión alta de CLDN18.2 tratados con inmunoterapia mostraron tendencia a peores resultados que los pacientes con tumores con baja expresión (mSG 16 vs 43 meses; P = 0,052).
-	Los datos apoyan la necesidad de estrategias terapéuticas guiadas por biomarcadores en GEA avanzado.

]]></description>
			<style id="elementor-post-13154">.elementor-13154 .elementor-element.elementor-element-3ce7a18b{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-658f317a > .elementor-widget-container{padding:0px 0px 20px 0px;}.elementor-13154 .elementor-element.elementor-element-4a299971{--display:flex;--flex-direction:column;--container-widget-width:100%;--container-widget-height:initial;--container-widget-flex-grow:0;--container-widget-align-self:initial;--flex-wrap-mobile:wrap;--gap:20px 40px;--row-gap:20px;--column-gap:40px;border-style:none;--border-style:none;--margin-top:0px;--margin-bottom:20px;--margin-left:0px;--margin-right:0px;--padding-top:20px;--padding-bottom:20px;--padding-left:30px;--padding-right:30px;}.elementor-13154 .elementor-element.elementor-element-4a299971:not(.elementor-motion-effects-element-type-background), .elementor-13154 .elementor-element.elementor-element-4a299971 > .elementor-motion-effects-container > .elementor-motion-effects-layer{background-color:#7A7A7A0D;}.elementor-13154 .elementor-element.elementor-element-2264f626{--display:flex;--justify-content:flex-start;--gap:5px 0px;--row-gap:5px;--column-gap:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-571428a8{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13154 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-13154 .elementor-element.elementor-element-241536ae{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13154 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-13154 .elementor-element.elementor-element-392a579f{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13154 .elementor-element.elementor-element-34dd77b0 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-13154 .elementor-element.elementor-element-4e9ff277{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13154 .elementor-element.elementor-element-5bb74bd8 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-13154 .elementor-element.elementor-element-67254483{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-33cb564e{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-4679cddc .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-13154 .elementor-element.elementor-element-4679cddc .elementor-button:hover, .elementor-13154 .elementor-element.elementor-element-4679cddc .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-13154 .elementor-element.elementor-element-4679cddc .elementor-button:hover svg, .elementor-13154 .elementor-element.elementor-element-4679cddc .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-13154 .elementor-element.elementor-element-41955f1d .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-13154 .elementor-element.elementor-element-41955f1d .elementor-button:hover, .elementor-13154 .elementor-element.elementor-element-41955f1d .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-13154 .elementor-element.elementor-element-41955f1d .elementor-button:hover svg, .elementor-13154 .elementor-element.elementor-element-41955f1d .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-13154 .elementor-element.elementor-element-67f1d66d{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:10px 10px;--row-gap:10px;--column-gap:10px;--padding-top:30px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13154 .elementor-element.elementor-element-9c6d187 > .elementor-widget-container{padding:5px 5px 5px 5px;border-style:solid;border-width:1px 1px 1px 1px;border-color:#4747475E;border-radius:46px 46px 46px 46px;}.elementor-13154 .elementor-element.elementor-element-59554da0 .elementor-icon-box-wrapper{text-align:start;}.elementor-13154 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title{margin-block-end:0px;}.elementor-13154 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title, .elementor-13154 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title a{font-size:13px;}.elementor-13154 .elementor-element.elementor-element-59554da0 .elementor-icon-box-description{font-size:14px;line-height:15px;}@media(max-width:1366px){.elementor-13154 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13154 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13154 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:1200px){.elementor-13154 .elementor-element.elementor-element-571428a8{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13154 .elementor-element.elementor-element-241536ae{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13154 .elementor-element.elementor-element-392a579f{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13154 .elementor-element.elementor-element-4e9ff277{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}}@media(max-width:1024px){.elementor-13154 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13154 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13154 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:767px){.elementor-13154 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13154 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13154 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13154 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}</style>							<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="13154" class="elementor elementor-13154" data-elementor-post-type="post">
				<div class="elementor-element elementor-element-3ce7a18b e-flex e-con-boxed e-con e-parent" data-id="3ce7a18b" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-658f317a elementor-widget elementor-widget-heading" data-id="658f317a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">Claudina 18.2 en adenocarcinoma gastroesofágico: prevalencia, solapamiento biomarcador e impacto clínico en cohorte europea</h2>				</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-4a299971 e-con-full e-flex e-con e-child" data-id="4a299971" data-element_type="container" data-e-type="container" data-settings="{&quot;background_background&quot;:&quot;classic&quot;}">
		<div class="elementor-element elementor-element-2264f626 e-con-full e-flex e-con e-child" data-id="2264f626" data-element_type="container" data-e-type="container">
		<div class="elementor-element elementor-element-571428a8 e-con-full e-flex e-con e-child" data-id="571428a8" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-c9b8ac6 elementor-widget elementor-widget-heading" data-id="c9b8ac6" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h5 class="elementor-heading-title elementor-size-default">Edición:</h5>				</div>
				</div>
				<div class="elementor-element elementor-element-522b0f51 elementor-widget elementor-widget-heading" data-id="522b0f51" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Publicación científica 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-241536ae e-con-full e-flex e-con e-child" data-id="241536ae" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-148cd8bf elementor-widget elementor-widget-heading" data-id="148cd8bf" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Fecha:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-2294010a elementor-widget elementor-widget-heading" data-id="2294010a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">01 de junio de 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-392a579f e-con-full e-flex e-con e-child" data-id="392a579f" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-31655606 elementor-widget elementor-widget-heading" data-id="31655606" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autores:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-34dd77b0 elementor-widget elementor-widget-heading" data-id="34dd77b0" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Terán E, Pazo R, Caritá L, Alsina M, Hierro C, Blanco C, Reboredo M, Landolfi S, Zucchiatti A, Visa L, Calvo A, López A, Vidal-Tocino R, Agra C, Alés I, Foti S, García-Paredes B, Genovesi V, Fornaro L, Sauri T, Macías I, Martínez E, Martínez J, Buges C, Ribera P, Herranz JM, Acosta D, Vivancos A, Tabernero J, Élez E, Tian TV, Macarulla T.</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-4e9ff277 e-con-full e-flex e-con e-child" data-id="4e9ff277" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-8521b33 elementor-widget elementor-widget-heading" data-id="8521b33" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autora de la revisión:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-5bb74bd8 elementor-widget elementor-widget-heading" data-id="5bb74bd8" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">María Nieva Muñoz, Hospital de la Santa Creu i Sant Pau. Barcelona (Miembro de la Asamblea General del Grupo TTD)</p>				</div>
				</div>
				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-67254483 e-flex e-con-boxed e-con e-parent" data-id="67254483" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-71cc5159 elementor-widget elementor-widget-text-editor" data-id="71cc5159" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>El estudio de Terán et al. analiza la expresión de CLDN18.2 en 563 pacientes europeos con adenocarcinoma gastroesofágico avanzado. La expresión alta de CLDN18.2 (≥75% de células tumorales) se detectó en el 48,3% de los casos, una prevalencia superior a la de los ensayos pivotales. La expresión se asoció con histología difusa y afectación peritoneal, y se solapó con otros biomarcadores en más del 20% de los pacientes. Mientras que CLDN18.2 no modificó los resultados con quimioterapia sola, sí se asoció con mejor respuesta a la terapia anti-HER2 y con una tendencia a peores resultados con inmunoterapia.</p><p><strong>Conclusiones:</strong></p><ul><li>La expresión alta de CLDN18.2 es más prevalente en Europa (48,3%) que en las series asiáticas y los ensayos pivotales (~24-38%).</li><li>Se asocia con histología difusa, células en anillo de sello y afectación peritoneal.</li><li>No tiene impacto en los resultados de supervivencia con quimioterapia de primera línea.</li><li>En los tumores HER2 positivos, aquellos con expresión alta de CLDN18.2 se asociaron con mejor mSLP con terapia anti-HER2 (17 vs 8,9 meses; P = 0,03).</li><li>Los pacientes con tumores expresión alta de CLDN18.2 tratados con inmunoterapia mostraron tendencia a peores resultados que los pacientes con tumores con baja expresión (mSG 16 vs 43 meses; P = 0,052).</li><li>Los datos apoyan la necesidad de estrategias terapéuticas guiadas por biomarcadores en GEA avanzado.</li></ul>								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-33cb564e e-flex e-con-boxed e-con e-parent" data-id="33cb564e" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-4679cddc elementor-align-center elementor-widget elementor-widget-button" data-id="4679cddc" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://grupottd.org/?post_type=articulos-comentados&#038;p=13148">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Ver artículo comentado TTD completo</span>
					</span>
					</a>
				</div>
								</div>
				</div>
				<div class="elementor-element elementor-element-41955f1d elementor-align-center elementor-widget elementor-widget-button" data-id="41955f1d" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://pubmed.ncbi.nlm.nih.gov/41604819/" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Enlace al artículo original</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-67f1d66d e-con-full e-flex e-con e-child" data-id="67f1d66d" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-9c6d187 elementor-widget elementor-widget-image" data-id="9c6d187" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://grupottd.org/wp-content/uploads/elementor/thumbs/fav_icon_TTD-r8xkio7ebt5062iunra09m8cc4544reqzr28q6uark.png" title="fav_icon_TTD" alt="fav_icon_TTD" loading="lazy" />															</div>
				</div>
				<div class="elementor-element elementor-element-59554da0 elementor-widget elementor-widget-icon-box" data-id="59554da0" data-element_type="widget" data-e-type="widget" data-widget_type="icon-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-icon-box-wrapper">

			
						<div class="elementor-icon-box-content">

									<h3 class="elementor-icon-box-title">
						<span  >
							Publicado por:						</span>
					</h3>
				
									<p class="elementor-icon-box-description">
						Grupo TTD					</p>
				
			</div>
			
		</div>
						</div>
				</div>
				</div>
				</div>
		]]></content:encoded>
					
					<wfw:commentRss>https://grupottd.org/claudina-18-2-en-adenocarcinoma-gastroesofagico-prevalencia-solapamiento-biomarcador-e-impacto-clinico-en-cohorte-europea/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Avances en primera línea con cadonilimab en cáncer gástrico y de la unión gastroesofágica HER2-negativo</title>
		<link>https://grupottd.org/avances-en-primera-linea-con-cadonilimab-en-cancer-gastrico-y-de-la-union-gastroesofagica-her2-negativo/</link>
					<comments>https://grupottd.org/avances-en-primera-linea-con-cadonilimab-en-cancer-gastrico-y-de-la-union-gastroesofagica-her2-negativo/#respond</comments>
		
		<dc:creator><![CDATA[Administrador CMLD Pruebas]]></dc:creator>
		<pubDate>Thu, 31 Jul 2025 09:43:57 +0000</pubDate>
				<category><![CDATA[Artículos comentados]]></category>
		<category><![CDATA[Biomarcadores]]></category>
		<category><![CDATA[Biomarcadores PD-L1]]></category>
		<category><![CDATA[Cadonilimab;Inmunoterapia PD-1 / CTLA-4]]></category>
		<category><![CDATA[Cáncer de la unión gastroesofágica]]></category>
		<category><![CDATA[Cáncer gástrico]]></category>
		<category><![CDATA[HER2 negativo]]></category>
		<category><![CDATA[HER2 positivo]]></category>
		<category><![CDATA[HER2-negativo]]></category>
		<category><![CDATA[HER2–]]></category>
		<category><![CDATA[HER2+]]></category>
		<category><![CDATA[Quimioterapia basada en oxaliplatino]]></category>
		<category><![CDATA[Terapias anti-HER2]]></category>
		<guid isPermaLink="false">https://grupottd.org/?p=6837</guid>

					<description><![CDATA[El ensayo fase III COMPASSION-15 marca un avance significativo en el manejo del adenocarcinoma gástrico y de la unión gastroesofágica (GEJ) avanzado HER2-negativo. Este estudio evaluó la combinación de cadonilimab, un anticuerpo biespecífico PD-1/CTLA-4, junto con quimioterapia basada en oxaliplatino y capecitabina frente a quimioterapia estándar más placebo.]]></description>
			<style id="elementor-post-6837">.elementor-6837 .elementor-element.elementor-element-6dc703cf{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-08fad68 > .elementor-widget-container{padding:0px 0px 20px 0px;}.elementor-6837 .elementor-element.elementor-element-1ed78a61{--display:flex;--flex-direction:column;--container-widget-width:100%;--container-widget-height:initial;--container-widget-flex-grow:0;--container-widget-align-self:initial;--flex-wrap-mobile:wrap;--gap:20px 40px;--row-gap:20px;--column-gap:40px;border-style:none;--border-style:none;--margin-top:0px;--margin-bottom:20px;--margin-left:0px;--margin-right:0px;--padding-top:20px;--padding-bottom:20px;--padding-left:30px;--padding-right:30px;}.elementor-6837 .elementor-element.elementor-element-1ed78a61:not(.elementor-motion-effects-element-type-background), .elementor-6837 .elementor-element.elementor-element-1ed78a61 > .elementor-motion-effects-container > .elementor-motion-effects-layer{background-color:#7A7A7A0D;}.elementor-6837 .elementor-element.elementor-element-bd65159{--display:flex;--justify-content:flex-start;--gap:5px 0px;--row-gap:5px;--column-gap:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-67135b81{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-57f68ba .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );color:var( --e-global-color-accent );}.elementor-6837 .elementor-element.elementor-element-73d4ab40 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );color:#646464;}.elementor-6837 .elementor-element.elementor-element-7ceccdd0{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-2d0ac1cc .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );color:var( --e-global-color-accent );}.elementor-6837 .elementor-element.elementor-element-62149c21 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );color:#646464;}.elementor-6837 .elementor-element.elementor-element-642aa385{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-4e6684cb .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );color:var( --e-global-color-accent );}.elementor-6837 .elementor-element.elementor-element-41eeff7c .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-6837 .elementor-element.elementor-element-226a882{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-6ac0eeed{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-26a7a298 .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-6837 .elementor-element.elementor-element-26a7a298 .elementor-button:hover, .elementor-6837 .elementor-element.elementor-element-26a7a298 .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-6837 .elementor-element.elementor-element-26a7a298 .elementor-button:hover svg, .elementor-6837 .elementor-element.elementor-element-26a7a298 .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-6837 .elementor-element.elementor-element-5902155b{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-4f6c5ca0 .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-6837 .elementor-element.elementor-element-4f6c5ca0 .elementor-button:hover, .elementor-6837 .elementor-element.elementor-element-4f6c5ca0 .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-6837 .elementor-element.elementor-element-4f6c5ca0 .elementor-button:hover svg, .elementor-6837 .elementor-element.elementor-element-4f6c5ca0 .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-6837 .elementor-element.elementor-element-63208e6{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:10px 10px;--row-gap:10px;--column-gap:10px;--padding-top:30px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-6837 .elementor-element.elementor-element-173ce77 > .elementor-widget-container{padding:5px 5px 5px 5px;border-style:solid;border-width:1px 1px 1px 1px;border-color:#4747475E;border-radius:46px 46px 46px 46px;}.elementor-6837 .elementor-element.elementor-element-151008c .elementor-icon-box-wrapper{text-align:start;}.elementor-6837 .elementor-element.elementor-element-151008c .elementor-icon-box-title{margin-block-end:0px;}.elementor-6837 .elementor-element.elementor-element-151008c .elementor-icon-box-title, .elementor-6837 .elementor-element.elementor-element-151008c .elementor-icon-box-title a{font-size:13px;}.elementor-6837 .elementor-element.elementor-element-151008c .elementor-icon-box-description{font-size:14px;line-height:15px;}@media(max-width:1366px){.elementor-6837 .elementor-element.elementor-element-57f68ba .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}.elementor-6837 .elementor-element.elementor-element-73d4ab40 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );}.elementor-6837 .elementor-element.elementor-element-2d0ac1cc .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}.elementor-6837 .elementor-element.elementor-element-62149c21 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );}.elementor-6837 .elementor-element.elementor-element-4e6684cb .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}}@media(max-width:1200px){.elementor-6837 .elementor-element.elementor-element-67135b81{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-6837 .elementor-element.elementor-element-7ceccdd0{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-6837 .elementor-element.elementor-element-642aa385{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}}@media(max-width:1024px){.elementor-6837 .elementor-element.elementor-element-57f68ba .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}.elementor-6837 .elementor-element.elementor-element-73d4ab40 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );}.elementor-6837 .elementor-element.elementor-element-2d0ac1cc .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}.elementor-6837 .elementor-element.elementor-element-62149c21 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );}.elementor-6837 .elementor-element.elementor-element-4e6684cb .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}}@media(max-width:767px){.elementor-6837 .elementor-element.elementor-element-57f68ba .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}.elementor-6837 .elementor-element.elementor-element-73d4ab40 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );}.elementor-6837 .elementor-element.elementor-element-2d0ac1cc .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}.elementor-6837 .elementor-element.elementor-element-62149c21 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );letter-spacing:var( --e-global-typography-a7220b8-letter-spacing );word-spacing:var( --e-global-typography-a7220b8-word-spacing );}.elementor-6837 .elementor-element.elementor-element-4e6684cb .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );letter-spacing:var( --e-global-typography-d3d4f5c-letter-spacing );word-spacing:var( --e-global-typography-d3d4f5c-word-spacing );}}</style>							<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="6837" class="elementor elementor-6837" data-elementor-post-type="post">
				<div class="elementor-element elementor-element-6dc703cf e-flex e-con-boxed e-con e-parent" data-id="6dc703cf" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-08fad68 elementor-widget elementor-widget-heading" data-id="08fad68" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">Avances en primera línea con cadonilimab en cáncer gástrico y de la unión gastroesofágica HER2-negativo</h2>				</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-1ed78a61 e-con-full e-flex e-con e-child" data-id="1ed78a61" data-element_type="container" data-e-type="container" data-settings="{&quot;background_background&quot;:&quot;classic&quot;}">
		<div class="elementor-element elementor-element-bd65159 e-con-full e-flex e-con e-child" data-id="bd65159" data-element_type="container" data-e-type="container">
		<div class="elementor-element elementor-element-67135b81 e-con-full e-flex e-con e-child" data-id="67135b81" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-57f68ba elementor-widget elementor-widget-heading" data-id="57f68ba" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h5 class="elementor-heading-title elementor-size-default">Edición:</h5>				</div>
				</div>
				<div class="elementor-element elementor-element-73d4ab40 elementor-widget elementor-widget-heading" data-id="73d4ab40" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Publicación científica 2025</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-7ceccdd0 e-con-full e-flex e-con e-child" data-id="7ceccdd0" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-2d0ac1cc elementor-widget elementor-widget-heading" data-id="2d0ac1cc" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Fecha:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-62149c21 elementor-widget elementor-widget-heading" data-id="62149c21" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">16 de septiembre de 2025</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-642aa385 e-con-full e-flex e-con e-child" data-id="642aa385" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-4e6684cb elementor-widget elementor-widget-heading" data-id="4e6684cb" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autor de la revisión:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-41eeff7c elementor-widget elementor-widget-heading" data-id="41eeff7c" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Dr. Juan José Reina Zoilo – Servicio de Oncología Médica, Hospital Universitario Virgen Macarena de Sevilla). Nature Medicine (abril 2025)</p>				</div>
				</div>
				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-226a882 e-flex e-con-boxed e-con e-parent" data-id="226a882" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-9566bc6 elementor-widget elementor-widget-text-editor" data-id="9566bc6" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>El ensayo fase III COMPASSION-15 marca un avance significativo en el manejo del adenocarcinoma gástrico y de la unión gastroesofágica (GEJ) avanzado HER2-negativo. Este estudio evaluó la combinación de cadonilimab, un anticuerpo biespecífico PD-1/CTLA-4, junto con quimioterapia basada en oxaliplatino y capecitabina frente a quimioterapia estándar más placebo. </p>
<p>En una cohorte de 610 pacientes no tratados previamente, el brazo cadonilimab logró una supervivencia global (SG) de 14,1 meses frente a 11,1 meses en el grupo control (HR 0,66; p&lt;0,001), con beneficios consistentes incluso en pacientes con baja expresión de PD-L1. La supervivencia libre de progresión (SLP) también mejoró (7,0 vs 5,3 meses), así como la tasa de respuesta objetiva (65,2% vs 48,9%) y la duración de la respuesta (8,8 vs 4,4 meses). </p>
<p>El perfil de seguridad mostró un incremento en eventos inmunomediados grado ≥3, fundamentalmente hematológicos, pero manejables clínicamente. </p>
<h5>Relevancia clínica </h5>
<p>Confirma el papel de la doble inhibición inmunitaria (PD-1 + CTLA-4) en tumores digestivos. Amplía opciones terapéuticas en pacientes HER2-negativos, especialmente aquellos con baja expresión de PD-L1. Plantea la necesidad de nuevos biomarcadores para seleccionar mejor a los candidatos a esta estrategia. Podría integrarse en los futuros algoritmos de primera línea para cáncer gástrico y GEJ avanzado. </p>
<p>Conclusión: Cadonilimab más quimioterapia representa una alternativa prometedora para pacientes con adenocarcinoma gástrico y GEJ avanzado HER2-negativo. Su beneficio en supervivencia global y progresión, junto a un perfil de toxicidad controlable, refuerza su potencial para convertirse en un nuevo estándar de tratamiento.</p>
<p><!-- /wp:paragraph --></p>								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-6ac0eeed e-flex e-con-boxed e-con e-parent" data-id="6ac0eeed" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-26a7a298 elementor-align-center elementor-widget elementor-widget-button" data-id="26a7a298" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://grupottd.org/articulos-comentados/clinical-characterization-of-fgfr2b-expression-in-patients-with-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma/">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Ver artículo comentado TTD completo</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-5902155b e-flex e-con-boxed e-con e-parent" data-id="5902155b" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-4f6c5ca0 elementor-align-center elementor-widget elementor-widget-button" data-id="4f6c5ca0" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12205640/pdf/main.pdf" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Enlace al artículo original</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-63208e6 e-con-full e-flex e-con e-child" data-id="63208e6" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-173ce77 elementor-widget elementor-widget-image" data-id="173ce77" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://grupottd.org/wp-content/uploads/elementor/thumbs/fav_icon_TTD-r8xkio7ebt5062iunra09m8cc4544reqzr28q6uark.png" title="fav_icon_TTD" alt="fav_icon_TTD" loading="lazy" />															</div>
				</div>
				<div class="elementor-element elementor-element-151008c elementor-widget elementor-widget-icon-box" data-id="151008c" data-element_type="widget" data-e-type="widget" data-widget_type="icon-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-icon-box-wrapper">

			
						<div class="elementor-icon-box-content">

									<h3 class="elementor-icon-box-title">
						<span  >
							Publicado por:						</span>
					</h3>
				
									<p class="elementor-icon-box-description">
						Grupo TTD					</p>
				
			</div>
			
		</div>
						</div>
				</div>
				</div>
				</div>
		]]></content:encoded>
					
					<wfw:commentRss>https://grupottd.org/avances-en-primera-linea-con-cadonilimab-en-cancer-gastrico-y-de-la-union-gastroesofagica-her2-negativo/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
